Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications

NCT ID: NCT03845907

Last Updated: 2020-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-19

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study performs the first clinical evaluation of the Gen1B (OA-16-1S) duplex OA/US probe. This probe includes design changes to improve reliability and performance compared to the Gen1 (OA-16-1) duplex OA/US probe. The performance of the Gen1 duplex probe is functionally equivalent to the PIONEER duplex probe (OA-15-3), which was used in previous clinical studies for suspicious breast masses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Unblinded feasibility study in healthy subjects
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Imagio Gen 1B

Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe

Group Type ACTIVE_COMPARATOR

Gen 1B

Intervention Type DEVICE

Diagnostic Ultrasound and Optoacoustic Imaging

Gen 1

Intervention Type DEVICE

Diagnostic Ultrasound and Optoacoustic Imaging

Imagio Gen 1

Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System

Group Type ACTIVE_COMPARATOR

Gen 1B

Intervention Type DEVICE

Diagnostic Ultrasound and Optoacoustic Imaging

Gen 1

Intervention Type DEVICE

Diagnostic Ultrasound and Optoacoustic Imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gen 1B

Diagnostic Ultrasound and Optoacoustic Imaging

Intervention Type DEVICE

Gen 1

Diagnostic Ultrasound and Optoacoustic Imaging

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a signed and dated informed consent, prior to initiation of any study-related activities.
* Is at least 18 years of age.
* Is willing to undergo an Imagio imaging evaluation and standard Ultrasound Evaluation of the breast and axillary lymph nodes.
* Is willing and able to comply with protocol-required scans.

Exclusion Criteria

* Is pregnant or lactating.
* Has a condition or impediment (i.e. insect bites, poison ivy, rash, open wounds, chafing of the skin, scar, tattoos, moles, breast implants within the previous 12 months, etc.) where the duplex probe will come in contact with the subject, which could interfere with the intended field of view.
* Is experiencing photo-toxicity associated with currently taking, or having taken, photosensitizing agents within the previous 72 hours such as sulfa, ampicillin, tetracycline.
* Is currently undergoing phototherapy.
* Has a history of any photosensitive disease (e.g., porphyria, lupus erythematosus) or undergoing treatment for a photosensitive disease and is experiencing photosensitivity.
* Has had an adverse reaction in the past to medical laser procedures, such as laser hair removal or laser tattoo removal.
* Has had a history of contact dermatitis induced by gold or chrome metal contact with skin.
* Has an acute or chronic hematoma and/or acute ecchymosis of the breast.
* Has had prior benign excisional breast biopsy within the past 18 months.
* Has nipple rings that cannot be removed or are not removed during Imagio evaluation.
* Currently has mastitis.
* Has focal pain in the breast.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seno Medical Instruments Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

A. Thomas Stavros, MD

Role: STUDY_DIRECTOR

Seno Medical

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seno Medical

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GEN1B-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CONFIDENCE Registry
NCT05084729 COMPLETED
OA for Breast Cancer NAC Response
NCT05337280 COMPLETED NA
Quantitative Subharmonic Breast Imaging
NCT01490892 COMPLETED PHASE4